by Brandon Tudor | Jul 26, 2026 | Blog
The 05/27/2026 article “GLP-1s Gain Traction for Treating Fatty Liver Disease” central message is that GLP-1 receptor agonists (particularly semaglutide/Wegovy and tirzepatide) are rapidly moving from “weight-loss drugs” to becoming mainstream...
by Brandon Tudor | Jul 24, 2026 | Blog
July 23, 2026: Medscape In Discussion: MASLD.This video speaks to when fatty liver appears incidentally on imaging, “just lose weight” isn’t enough. Dr. Danielle Brandman of Weill Cornell Medicine explains how to use FIB-4, FibroScan, and ELF to...
by David Sires | Jul 22, 2026 | Blog
Summary: “Researchers Recommend Dynamic Classification for Steatotic Liver Disease” Published: July 21, 2026 (CLP Magazine)Based on research from: Charité – Universitätsmedizin Berlin, published in eGastroenterology The big idea The researchers argue that...
by Pete Celano | Jul 20, 2026 | Blog
The paper “Steatotic Liver Disease Has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the U.S. Veterans Health System” (American Journal of Gastroenterology, 2026) analyzed all U.S. Veterans Health Administration patients with cirrhosis...
by David Sires | Jul 17, 2026 | Blog
A new UC San Diego-led study titled “GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease” provides encouraging evidence that GLP-1 receptor agonists may benefit patients with advanced metabolic dysfunction–associated steatohepatitis (MASH),...
by Brandon Tudor | Jul 15, 2026 | Blog
